The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma
Open accessPublished version of a preprint
Abstract
Medulloblastoma (MB) is the most prevalent brain cancer in children. Four subgroups of MB have been identified; of these, Group 3 is the most metastatic. Its genetics and biology remain less clear than the other groups, and it has a poor prognosis and few effective treatments available. Tumor hypoxia and the resulting metabolism are known to be important in the growth and survival of tumors but, to date, have been only minimally explored in MB. Here we show that Group 3 MB tumors do not depend on the canonical transcription factor hypoxia-inducible factor-1α (HIF-1α) to mount an adaptive response to hypoxia. We discovered that HIF-1α is rendered inactive either through post-translational methylation, preventing its nuclear localization specifically in Group 3 MB, or by a low expression that prevents modulation of HIF-target genes. Strikingly, we found that HIF-2 takes over the role of HIF-1 in the nucleus and promotes the activation of hypoxia-dependent anabolic pathways. The exclusion of HIF-1 from the nucleus in Group 3 MB cells enhances the reliance on HIF-2’s transcriptional role, making it a viable target for potential anticancer strategies. By combining pharmacological inhibition of HIF-2α with the use of metformin, a mitochondrial complex I inhibitor to block respiration, we effectively induced Group 3 MB cell death, surpassing the effectiveness observed in Non-Group 3 MB cells. Overall, the unique dependence of MB cells, but not normal cells, on HIF-2-mediated anabolic metabolism presents an appealing therapeutic opportunity for treating Group 3 MB patients with minimal toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Group 3 MB are sensitive to oxygen variations and do not express HIF-1 target genes. a Schematic distribution of the different MB subgroups according to the vascular system based on [49]. b Heatmap of the RNA expression of genes from GSE85217 with 763 primary samples from MB patients from Group 3, Group 4, SHH Group and WNT Group MB [31]. The heatmap focused specifically on target genes of HIF-1. Expression of the genes was compared using Phantasus (v1.19.3). Median expression is represented for each group. p-values were obtained using the Limma differential expression. c–f (c) DAOY, (d) ONS-76, (e) HDMB-03 and (f) D-458 cells were incubated in 21%, 6% and 1% O2 for 24, 48 and 72 h. Cell viability (%) was measured using an ADAM cell counter. The 2-way ANOVA is representative of at least three independent experiments. *p < 0.05, **p < 0.005 and ****p < 0.0001. g Comparison of cell viabilities (%) of DAOY, ONS-76, HDMB-03 and D-458 cells incubated for 72 h in 1% O2. The 2-way ANOVA is representative of at least three independent experiments. *p < 0.05, **p < 0.005 and ****p < 0.0001. h–k (f) DAOY, (g) ONS-76, (h) HDMB-03HDMB-03 and (i) D-458 cells were seeded at the same density and incubated in 21%, 6% and 1% O2 for 24, 48 and 72 h. The 2-way ANOVA is representative of at least three independent experiments. **p < 0.005, ***p < 0.0005 and ****p < 0.0001. l DAOY, ONS-76, HDMB-03, and D-458 cells were incubated in normoxia (Nx, 21% O2) for 24 h and hypoxia (Hx, 1% O2) for 24, 48 and 72 h. Cell lysates were analyzed by immunoblotting for HIF-1α and HIF-2α. Tubulin was used as a loading control. m, n Heatmap of the RNA expression of genes in DAOY, ONS-76, HDMB-03 and D-458 cells exposed to Nx or Hx, compared with PDX3 and PDX7 from Group 3 MB. The heatmap focused specifically on target genes of (m) HIF-1 and (n) HIF-2. Expression of the genes was compared using Phantasus (v1.19.3). p-values were obtained using the Limma differential expression.](https://figures.cochat.ai/paper-figures/a8ebed7a075a42e49267cdbcb7393aaf/hif-1-inactivation-empowers-hif-2-to-drive-hypoxia-adaptation-in-aggressive-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, in certain contexts, such as in renal cancer or medulloblastoma where HIF-1α is lost or inactivated, HIF-2α acquires the dominant role in regulating the hypoxia response, suggesting a measure of redundancy between the two isoforms [5, 6].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“Several classes of HIF inhibitors have been investigated, including small molecules, peptides, and biologics [27 – 29].”
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Molecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936 · cited 2×
“Each subgroup is characterized by speci fi c genetic alterations, gene expression patterns, and signaling pathway dysregulations, which in fl uence tumor development, progression, and response to therapy [2 – 5].”
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676 · cited 3×
“Tumor hypoxia, a condition characterized by insuf fi cient oxygen supply within the tumor microenvironment, is a hallmark feature of solid tumors [6, 7].”
Self-citationHypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354 · cited 1×
“The best characterized are clear cell renal cell carcinoma [23], neuroblastoma [24], and glioma [25].”
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
The whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112 · cited 2×
“Each subgroup is characterized by speci fi c genetic alterations, gene expression patterns, and signaling pathway dysregulations, which in fl uence tumor development, progression, and response to therapy [2 – 5].”
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
The role of oxygen availability in embryonic development and stem cell function
Simon, M. C., & Keith, B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2354 · Cited by 967
Research works printed but not linked: 1
- Brahimi-Horn M, Laferrière J, Mazure N & Pouysségur, J. Tumor angiogenesis. In: Marmé D & Fusenig N, editors. Springer; 2007. pp. 171–94.
Cited by
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Bellazzo, A., Montico, B., Guerrieri, R., Colizzi, F., Steffan, A., Polesel, J., & Fratta, E. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02173-4 · Cited by 17
Multifunctional Copper Ion‐Mediated Carrier‐Free Scutellarin Hydrogel for Diabetic Wound Healing
Xia, F., Tu, Q., Liu, Y., Zhang, J., Fan, M., Zhong, L., Fu, Y., Guo, P., Pang, H., Meng, Y., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202503562 · Cited by 14
The role of hypoxia-inducible factor-1α on colon cancer progression and metastasis
Saadh, M. J., Ahmed, M. H., Albadr, R. J., Sanghvi, G. V., Roopashree, R., Kashyap, A., Sabarivani, A., Rizaev, J. A., Taher, W. M., Alwan, M., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02906-y · Cited by 6
Silina, M. V., Dzhalilova, D. S., & Makarova, O. V. (2025) · Moscow University Biological Sciences Bulletin · doi:10.3103/s0096392525600681 · Cited by 4
Metadata
- Authors
- Contenti, J., Guo, Y., Larcher, M., Mirabal-Ortega, L., Rouleau, M., Irondelle, M., Tiroille, V., Mazzu, A., Duranton-Tanneur, V., Pedeutour, F., Ben-Sahra, I., Lago, C., Leva, G., Tiberi, L., Robert, G., Pouponnot, C., Bost, F., & Mazure, N. M.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- University of Trento (IT)
- Corresponding author
- Contenti, J.
- Mazure, N. M.
- ORCID
- Venue
- Cell Death Discovery
- Published
- 2024-07-24
- Volume
- 10
- Issue
- 1
- Pages
- 338-338
- ISSN
- 2058-7716 (ISSN-L)
- PMC
- PMC11269614
- OpenAlex
- W4400934698
- Cited by
- 6
- References
- 49
- Citations by year
- 2026: 2 · 2025: 4
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death Discovery (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- PubMed Central (submittedVersion)
- HAL (submittedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Northwestern University
- Infrastructures en Biologie Santé et Agronomie
- Institut National de la Santé et de la Recherche Médicale (U1065)
- Fondation ARC pour la Recherche sur le Cancer
- Ligue Contre le Cancer
- China Scholarship Council
- Centre National de la Recherche Scientifique
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health
- Robert H. Lurie Comprehensive Cancer Center
- National Cancer Institute (R00CA194192)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- medulloblastoma, Group 3 medulloblastoma, hypoxia, HIF-1α, HIF-2α, nuclear localization, anabolic metabolism, metformin, mitochondrial complex I inhibition, HIF-2α inhibition, pediatric brain tumors, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma. https://app.cochat.ai/papers/10.1038/s41420-024-02100-5
- The paper
- Contenti, J., Guo, Y., Larcher, M., Mirabal-Ortega, L., Rouleau, M., Irondelle, M., Tiroille, V., Mazzu, A., Duranton-Tanneur, V., Pedeutour, F., Ben-Sahra, I., Lago, C., Leva, G., Tiberi, L., Robert, G., Pouponnot, C., Bost, F., & Mazure, N. M. (2024). HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma. Cell Death Discovery. https://doi.org/10.1038/s41420-024-02100-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.